Business Wire

1E

11.5.2021 16:37:09 CEST | Business Wire | Press release

Share
1E Challenges DEM Market to Deliver More, Launching New Unified eXperience Management Category

1E , innovators in endpoint management, today announced Unified eXperience Management (UXM) , a new category that seeks to address the siloed approach inherent in tools in the Digital Experience Monitoring (DEM) space.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005842/en/

Due to the relative immaturity of the Digital Experience Management category, most tooling is focused on identifying and reporting on the scale of the problem, scoring, and issue identification. These tools create analytics silos that give insight, but are uncoupled from the automation technology that can actually improve end-user experience at an enterprise scale. Meanwhile, employees are becoming increasingly more frustrated, with 56% feeling dissatisfied with their IT experience . Organizations looking to improve the digital experience of all their employees need to move beyond analytics and embrace automation to resolve these issues.

Furthermore, this siloed approach of today’s DEM solutions neglects the substantial investment most large organizations have made into platforms like ServiceNow and Microsoft. The industry needs a solution that can leverage these investments to be part of the solution rather than ignore them.

1E is introducing the UXM category in response to these issues that unifies Digital Experience Monitoring with all the other aspects of IT required to positively impact the user’s experience. Unified eXperience Management comprises Experience Monitoring, Employee Engagement, Diagnostic and Remediation tooling, and Configuration Policy to ensure that once an issue is fixed on one machine it is applied to all machines on an ongoing basis. Deep and rich integration with service desk and UEM platforms like ServiceNow and Microsoft Endpoint Manager enable IT workers dealing with incidents to have access to insights and a shared library of fixes to ensure that end-user issues are dealt with in real-time.

“If a Digital Experience initiative can identify experience issues but has no clear line of sight to remediating them, it will deliver zero value; No employee ever wished IT had a better analytics solution,” said Sumir Karayi, CEO and founder of 1E. “They want less frustrating experiences, they want fewer disruptions. For this, IT needs to take a step beyond analytics that identifies issues, to an initiative that leverages automation to predict and improve experiences. That is how we view Unified eXperience Management -- proactive, real time, holistic action across all endpoints.”

To accompany the launch of the category, 1E’s Product Chief Technologist, Bogdan Udrea, will host a webinar exploring UXM and how it can help organizations enable a modern, hybrid workplace on May 18 at 11 a.m. ET. To attend, please visit: https://info.1e.com/webinar-go-beyond-digital-experience-management-what-is-uxm

This coincides with the latest release of 1E Tachyon , which brings new UXM capabilities to market. Tachyon 5.2 contains a unified device view that expedites troubleshooting and remediation of an endpoint on a single pane of glass. The latest release also introduces a new persona management capability, allowing IT to better understand the needs and experience challenges of different cohorts of employees.

Product Marketing Director, Michael Wright, will be launching Tachyon 5.2 on May 20th at 11am ET. To attend the launch event, please visit: https://info.1e.com/launch-showcase-tachyon-5.2-discover-complete-device-visibility

WFA Research: https://www.1e.com/wfa-research-2021/

About 1E

1E the innovators in endpoint management that supports the work from anywhere enterprise, so employees are secure, supported, and productive wherever they want to be. The 1E Tachyon Platform provides real-time diagnosis, remediation and automation that fixes issues, fast and without interruption. It puts employees in control, through self-service, self-heal and sentiment monitoring to understand how they really feel and reduces help desk calls and ultimately costs. That’s why more than 1,700 organizations in 42 countries trust 1E to help them manage 14 million endpoints seamlessly. For more information, visit www.1E.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 11:15:00 CEST | Press release

The first SaaS SuperApp for startups and VCs capitalizes on a $25M round a from Nimbus Capital and a +15% stock surge, unveiling a v3/v4 roadmap that bridges public equity with digital asset liquidity. HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026061293689

Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 09:35:00 CEST | Press release

Agricultural innovation leader to contribute with agronomic expertise in building accurate crop health, pest forecasting and heat stress models India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of

Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release

The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release

AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye